Thank you for being one of our most loyal readers. Please consider supporting community journalism by subscribing.
CLAYTON — Grifols’ Clayton plant has begun production of a COVID-19 treatment.
The company expects the first doses to be available in July as part of a clinical trial.
The treatment is a hyperimmune immunoglobulin, which doctors use mainly to treat infectious agents, immunodeficiencies, neurological conditions stemming from autoimmune diseases, and weakened immune systems from cancer treatments.
Grifols derived the treatment from the plasma of people who have overcome COVID-19. It is the first drug developed specifically to combat COVID-19, the company said.
Separately, Grifols is moving forward with a clinical trial in Spain to assess the effectiveness of high-dose intravenous immunoglobulin to stabilize or improve the condition of COVID-19 patients.